
Union Therapeutics has not been involved in the development of Covid-19 treatments for many months, but nonetheless, the company is pacing forward at full speed and currently taking one of its drugs through phase I.
Now the company has taken another step down the Covid-19 path with a major options agreement with Texan company TFF Pharmaceuticals, which may ultimately cost Union Therapeutics up to USD 210m.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app